Infection with HIV results in an incremental loss of T helper cell (TH) function, which can occur years before CD4 cell numbers are critically reduced and AIDS is diagnosed. All TH function is not affected, however, because B cell activation and hypergammaglobulinema are also characteristic of this period. Recently, in a murine model of AIDS an early loss in production of the CD4 cytokines IL-2 and IFN-'y was correlated with an increase in the B cell stimulatory cytokines IL4, IL-5, and IL-10. We therefore assessed the production of IL4 generated by PBL from HIV-seropositive (HIV+) individuals who did not have AIDS, yet who exhibited different TH functional categories based on their IL-2 production profiles. We observed that the decreases in recall antigen-stimulated IL-2 production were accompanied by an increase in IL4 production. The loss of recall antigen-stimulated responses in HIV + individuals could be reversed in vitro by anti-IL4 antibody. Our results suggest that the TH functions assessed by IL4 production replace the normally dominant TH function of antigen-stimulated IL-2 production in the progression toward AIDS, and raise the possibility of cytokine cross-regulation in AIDS therapy. (J. Clin. Invest. 1993. 91:759-765.) Key words: interleukin-2 * interleukin4 * interleukin-10 * human immunodeficiency virus infection * T lymphocytes
Introduction
It is well established that defects in T helper (TH)' immune function can be detected in HIV seropositive (HIV +) patients long before a decline in the number of CD4+ T lymphocytes is evident (1) (2) (3) (4) . In particular, we have previously demonstrated that asymptomatic, HIV + individuals can be divided into four distinct subgroups, based on in vitro TH function oftheir PBL, as assessed by IL-2 production and proliferation in response to: recall antigens such as tetanus toxoid and influenza A virus (FLU); irradiated, HLA-disparate PBL (ALLO); and PHA (4) . Individuals whose PBL generated positive responses to all which exhibit an inhibitory effect on TH lymphocytes (23) (24) (25) . Recent evidence demonstrating the independent and reciprocal production of TH 1 and TH2 cytokines by clones of murine (26) (27) (28) (29) (30) (31) (32) and human (32-39) CD4 + cells led us to reexamine the above categories of HIV-induced TH dysregulation for production of the TH2 cytokine IL-4. In the present study we have tested whether the loss of IL-2 production characteristic of HIV infection is associated with augmented production of IL-4. Our results support the hypothesis that the earlier stages of HIV infection are dominated by production of IL-4, with concomitant inhibition of IL-2 cytokines (40) . This cytokine profile has been postulated to indicate a switch from a "TH-1-like" to a "TH-2-like" cytokine pattern.
Methods
Patients and clinical evaluation. HIV + patients were obtained from Wilford Hall United States Air Force (USAF) Medical Center, Lackland Air Force Base, TX. Individuals were diagnosed as being HIV infected if they had anti-HIV antibodies demonstrated on two specimens tested by the HIV enzyme immunoassay (Abbott Laboratories, Irving, TX) and confirmed by Western blot analysis (Roche Biomedical Laboratories, Burlington, NC). Western blots were considered positive if they showed at least two of the following three bands reactive: p24, gp41, and gpl20 or gpl60. Patients were classified according to Walter Reed staging system (41 ) . The HIV-seronegative (HIV -) control donors were normal healthy volunteers. Lymphocyte counts and T cell subsets were determined using laser-based flow cytometry (Epics Profile; Coulter Electronics, Inc., Hialeah, FL), and OKT4A (anti-CD4) and OKT8 (anti-CD8) monoclonal antibodies (Orthodiagnostics Systems, Raritan, NJ). All patient and control studies were approved by the Institutional Review Boards ofboth the National Cancer Institute and the U. S. Air Force.
Processing of blood. Whole blood from HIV + individuals was drawn in tubes containing heparin (Vacutainer; Becton-Dickinson & Co., Rutherford, NJ) and shipped from Lackland, TX to Bethesda, MD, overnight at ambient temperature. Whole blood from HIV -individuals was collected in the same fashion and allowed to sit overnight at ambient temperatures. PBL were separated on lymphocyte separation medium (LSM; Organon Teknika Corp., Durham, NC), washed twice in PBS, and resuspended at 3 X 106/ml in RPMI 1640 (Gibco Laboratories, Grand Island, NY) containing 0.5% penicillin, 0.5% streptomycin, 1% glutamine, and 10 mM Hepes. Viable cells counts were determined by trypan blue exclusion.
IL-2 production and proliferation. The ability of PBL to produce antigen-induced IL-2 or to proliferate was determined by culturing the PBL at 370C in a moist, 7% CO2 atmosphere. PBL were either unstimulated, or were stimulated with: FLU (A/Bangkok RX73 H3N2) (1:500 concentration); 5,000 rad ALLO PBL from unrelated HIVdonors; or PHA diluted 1:100 (Gibco Laboratories). For IL-2 production, 3 x 105 PBL were cultured in 96-well, flat-bottom culture plates (Costar Corp., Cambridge, MA) for 7 d in the presence of 2 ,gg/ml of the human anti-IL-2 receptor antibody anti-Tac, to prevent IL-2 consumption by the stimulated cells (4). For IL-2 production, culture supernatants were frozen and stored at -20'C until assayed for IL-2 content. The IL-2 assays consisted of culturing 8 x 103 ofthe IL-2-dependent cytotoxic T lymphocyte line (CTLL) cell line per well in 96-well, flat-bottom microtiter plates, in the presence of four twofold dilutions of unstimulated or antigen-stimulated culture supernatants, as previously described (4). 24 h later, the cultures were pulsed with 1 0Ci of [3H ] thymidine, and harvested after 18 h using a 96-well cell harvester (Tomtec Inc., Orange, CT). 3H determinations were made using a spectrometer (Betaplate; Pharmacia LKB Biotechnology, Piscataway, NJ). In the assays in which inhibition of FLU stimulated proliferation was reversed by anti IL-4 antibody, PBL were stimulated for 5 d with CO2 atmosphere. PBL were either unstimulated or were stimulated with PHA diluted 1:100 (Gibco Laboratories). The culture media consisted of RPMI 1640 (Gibco Laboratories). Supernatants were harvested after 80 h of culture, because kinetic studies indicated that 80 h was the optimal time for assessing lymphokines detected by CT.h4S
cells (see Fig. 1 A) Supernatant dilutions we can stimulate IL-2 production with FLU and other recall antigens, but are unable to detect FLU-stimulated IL-4 production using PBL from either HIV -or HIV + individuals (data not shown). This is consistent with other studies in which IL-4 was not detected by stimulation with recall antigens (45) . Second, we can generate PHA stimulated-IL-2 production using unfractionated PBL or PBL depleted of either CD4 + or CD8 +, with PBL from + / + / + HIV + individuals or HIV-donors (see Fig. 2 ). Third, proliferation of the CT.h4S cell line was obtained (in the same culture supernatants) using PHA-stimulated unfractionated PBL or PBL depleted of CD8 + cells, but not PBL depleted of CD4+ cells (see Fig. 2 ). These findings demonstrate that both CD4+ and CD8+ cells produce IL-2 when stimulated with PHA, whereas only CD4+ cells produce IL-4 when stimulated with PHA. Fourth, FLU-IL-2 production requires previous exposure to influenza antigens, and is mediated by self-restricted CD4+ but not by CD8 + cells (46 The titration curves for responses of PBL from an HIV -control donor and from HIV + individuals representative of the three distinct IL-2 functional patterns described above are shown in Fig. 3 . PBL from both HIV -control donors and from HIV + donors categorized as + / + / + produced appreciable IL-2 in response to stimulation with FLU, ALLO, or PHA (Fig. 3,  A and B) . IL-4 production was low in these individuals, because CT.h4S proliferation was observed only at the 1:2 dilution of supernatant. In marked contrast to these two groups, HIV + individuals who did not generate IL-2 to FLU, but who produced IL-2 in response to ALLO and PHA (-/ + / + by our (Fig. 3 D) .
We plotted the units ofFLU-IL-2 generated as a function of the units of PHA-IL-4 produced for each of the 18 HIV -and 45 HIV + individuals. As shown in Fig. 4 , three distinct patterns of cytokine production were observed: (Fig. 5) . Assessment of IL-2 production by the stimulator panel demonstrated that donor 1 was + / +/+, donors 2, 3, and 5 were -/++, and donor 4 was --/ + by IL-2 production. Thus, the inverse correlation between IL-2 produced in response to FLU and IL-4 produced in response to PHA appeared to be maintained in these studies of IL-4 mRNA levels.
Restoration ofantigen-stimulatedproliferation in IL-2-deficient patients by stimulation ofthe PBL in presence ofan anti IL-4 antibody. To test whether cytokine cross-regulation could account for the loss of IL-2 production to FLU in -/+/+ patients, PBL from six -/ + / + HIV + individuals were stimulated with FLU in the presence of antibodies to human IL-4, IFN-y, and TGF-3. Anti-IFN-,y had no effect on the FLU responses of any of the patients (Fig. 6) . Anti-TGF-3 restored IL-2 production in only one individual, which may indicate that TGF-f contributes to TH dysregulation in some HIV + patients and is consistent with a previous report on the immunosuppressive effects of TGF-f3 (22) . In contrast, anti-IL-4 restored FLU-stimulated proliferative responses in PBL from five of these six patients (Fig. 5) (4) .
The mechanism responsible for the switch from a predominance of IL-2 to IL-4 production is not known, but could involve TH1-TH2 cross-regulation by cytokines such as IL-10. IL-10 has been demonstrated to decrease TH 1 cytokine production in both murine (28, 29) and human (38, 39) immune systems. Thus, mice infected with the murine retrovirus LP-BM5, which induces immunodeficiency and B cell hyperplasia (48) , exhibit increased IL-4 and IL-10 production and decreased IL-2 production with progression of disease (31 (51, 52) and exhibited an IL2 > IL-4 functional profile (Clerici, M., and G. M. Shearer, unpublished observations). These individuals were also virus negative in the blood by PCR assay. Two of the first six individuals followed longitudinally seroconverted and became PCR+ at the time of seroconversion (51, 52) . One of these two donors lost HIV-specific TH function at the time of PCR and seroconversion, and subsequently developed AIDS. Our results are consistent with a recent work by Yamamura et al. (35) , which described in leprosy a TH 1 pattern of cytokine production representative of a protective state, and a TH2 pattern associated with progression of disease. Thus, the loss of recall antigen-stimulated IL-2 production with a concomitant increase in IL-4 production is not necessarily unique to HIV infection and may be observed in other conditions that involve chronic stimulation of the immune system.
The present study suggests that cytokine cross-regulation can contribute to the loss of TH function of HIV + individuals before CD4 counts are appreciably reduced. It may be possible to stage HIV + patients by TH function, based on the relative amounts of cytokines that their PBL produce after in vitro stimulation. Studies are planned to test for IL-IO production, a cytokine that could be important in TH cross-regulation during AIDS progression. Our finding that the IL-4 > IL-2 pattern could be reversed by stimulating -/ + / + HIV + individuals' PBL in the presence of an anti-IL-4 antibody is consistent with the study in leprosy (35) , suggests that cytokine cross-regulation is involved in TH dysregulation in HIV + individuals, and raises the possibility of immunotherapy in HIV disease, based on cytokine cross-regulation.
